When Acne on AndroGel (testosterone topical) Becomes a Reason to Stop

By
Published Updated Last reviewed
Medication safety clinical consultation image for When Acne on AndroGel (testosterone topical) Becomes a Reason to Stop

When Acne on AndroGel (testosterone topical) Becomes a Reason to Stop

At a glance

  • Incidence on AndroGel: Acne or oily skin reported in approximately 5-10% of patients in the key AndroGel phase III registration trial, with higher rates in younger patients and those titrated above 7.5 g/day. See the FDA-approved AndroGel label for the full adverse event table.
  • Typical onset: 4-12 weeks after initiation or dose increase.
  • First-line management: Topical retinoids or benzoyl peroxide; verify serum DHT and free testosterone are not supratherapeutic.
  • Escalation trigger: Nodular lesions, spreading truncal involvement, or Grade 3 severity persisting beyond 8 weeks on first-line dermatologic therapy.
  • Discontinuation threshold: Cystic or scarring acne, failed two treatment lines, or documented quality-of-life impairment meeting dermatology referral criteria after minimum 12 weeks of managed therapy.
  • Preferred switch: Testosterone cypionate IM or pellet formulation, which produces lower peak DHT fluctuations per dose cycle in some patients.

Why AndroGel Specifically Drives Acne

Testosterone applied to skin undergoes local 5-alpha reduction to dihydrotestosterone (DHT) in the dermis and subcutis before entering systemic circulation. DHT binds androgen receptors in sebaceous glands with approximately five times the affinity of testosterone itself, directly upregulating sebum production and follicular keratinocyte proliferation. The FDA package insert for AndroGel 1% notes that DHT levels rise proportionally with dose and that the transdermal route produces a DHT-to-testosterone ratio meaningfully higher than intramuscular delivery. This is not a minor pharmacokinetic footnote. It explains why some patients who tolerate injectable testosterone without significant skin changes develop persistent acne on equivalent serum testosterone doses delivered transdermally.

The Endocrine Society Clinical Practice Guideline on testosterone therapy in men explicitly identifies acne as an androgen-mediated adverse effect and recommends checking serum DHT when acne is present, because supratherapeutic DHT, not just elevated total testosterone, is the primary driver. A serum DHT above 3,000 pg/mL during topical therapy should prompt either dose reduction or route change before any dermatologic escalation.

Grading the Acne Before Deciding Anything

Severity grading is the first clinical step. Stopping AndroGel for comedonal or mild inflammatory acne is not supported by evidence and deprives patients of a therapeutic benefit they were prescribed TRT to receive. The Global Acne Grading System (GAGS) and the Investigator Global Assessment (IGA) scale used in FDA acne trials both stratify as follows:

  • Grade 1 (mild): Open or closed comedones, fewer than 20 lesions, no nodules.
  • Grade 2 (moderate): 20-100 inflammatory papules or pustules, scattered on face and possibly trunk.
  • Grade 3 (severe): More than 100 inflammatory lesions, nodules present, truncal spread.
  • Grade 4 (very severe): Nodulo-cystic acne, confluent plaques, sinus tracts, active scarring.

Grades 1 and 2 warrant dermatologic co-management, not discontinuation. Grades 3 and 4 that persist after two sequential treatment regimens enter the genuine discontinuation conversation. The American Academy of Dermatology acne guidelines define treatment-resistant acne as failure of a topical retinoid plus either topical or oral antibiotics for eight or more weeks, a benchmark applicable directly to TRT-induced acne.

The Minimum Time Frame Before Stopping Is Appropriate

Eight weeks is an insufficient trial period to conclude that acne is intractable on AndroGel. Here is why. The skin's sebaceous response to androgen stimulation takes two to four weeks to manifest, and topical retinoids require six to twelve weeks to produce measurable lesion reduction per the AAD treatment guidelines. Stopping the drug at week six because acne has not yet responded to a retinoid started at week four is a logical sequencing error.

A clinically defensible minimum timeline before discontinuation looks like this:

  1. Weeks 1-4: Acne appears or worsens. Begin topical benzoyl peroxide 5% and a topical retinoid. Check serum DHT. If DHT is supratherapeutic, reduce AndroGel dose by one step (e.g., 7.5 g to 5 g/day) and reassess in four weeks.
  2. Weeks 4-12: If Grade 1-2 acne persists without nodules, continue topical therapy. If Grade 2-3 with pustules, add oral doxycycline 100 mg twice daily per AAD antibiotic guidance. Refer to dermatology.
  3. Weeks 12-16: If Grade 3 or higher persists despite the above, or if scarring is developing, the discontinuation or route-switch conversation is now appropriate.
  4. Week 16 onward: Continued Grade 3-4 acne with failed two sequential regimens is a clear discontinuation or route-change threshold by any reasonable clinical standard.

The Endocrine Society guideline does not set an exact week-by-week calendar for acne management, but it does state that testosterone therapy should be discontinued when adverse effects are not manageable with standard approaches, with the word "manageable" doing significant clinical work.

Lab Abnormalities That Accelerate the Decision

Acne alone is a dermatologic complaint. Acne plus lab abnormalities changes the risk calculus materially. Specific findings that move the timeline forward:

  • Serum DHT > 3,000 pg/mL: A well-documented association with androgen-mediated skin effects. The Bhasin et al. testosterone trials demonstrated dose-dependent DHT elevation with topical testosterone. If DHT remains elevated after a dose reduction and route change is refused by the patient, discontinuation becomes the only remaining option.
  • Hematocrit > 54%: While not directly causing acne, erythrocytosis co-occurring with severe acne on high-dose transdermal testosterone indicates systemic androgen excess. The FDA AndroGel label lists hematocrit elevation as a reason to reduce dose or discontinue. Combined with cystic acne, this picture is a strong prompt to stop the transdermal route immediately.
  • LFT elevation if oral isotretinoin is being considered: Isotretinoin for severe TRT-induced acne requires normal liver function at baseline, per FDA isotretinoin prescribing information. If hepatotoxicity is present from any cause, this limits the pharmacologic toolkit.

Quality-of-Life as a Legitimate Discontinuation Criterion

Prescribers sometimes underweight patient-reported burden. Acne on the face, chest, and upper back in a patient returning to work or managing intimate relationships carries documented psychosocial impact. The Cardiff Acne Disability Index and the Dermatology Life Quality Index (DLQI) both quantify this. A DLQI score above 10 indicates "very large" quality-of-life impairment and corresponds to the threshold at which dermatologists routinely consider isotretinoin. When TRT is the upstream cause and acne is refractory, a DLQI above 10 persisting beyond 12 weeks of active therapy is a reasonable and defensible discontinuation threshold in its own right, independent of lesion grade.

This matters because some patients present with Grade 2 acne that is objectively moderate but psychologically devastating given their profession, social context, or history with skin disease. Their quality-of-life data should carry weight in the discontinuation conversation. The Endocrine Society guideline supports individualized benefit-risk assessment that incorporates patient-reported outcomes, not just clinical scales.

What to Switch To Before Stopping Entirely

Full discontinuation of testosterone therapy carries its own risks in patients with documented hypogonadism, including return of symptoms, bone density loss over time, and mood effects. The Testosterone Trials (TTrials) demonstrated meaningful benefits of TRT in older hypogonadal men across multiple domains. Stopping prematurely to avoid acne trades one problem for several others.

The more evidence-informed path for most patients is a route change:

  • Intramuscular testosterone cypionate or enanthate: Delivers testosterone in depot form, producing lower sustained DHT-to-testosterone ratios compared to daily transdermal application. A pharmacokinetic comparison published in the Journal of Clinical Endocrinology and Metabolism confirmed that serum DHT is proportionally higher with transdermal versus intramuscular routes at equivalent testosterone targets.
  • Testosterone pellets (subcutaneous): Slower release, stable serum levels, and lower DHT variability versus gel. Less studied specifically for acne outcomes but mechanistically reasonable.
  • Testosterone nasal gel (Natesto): Delivers lower total systemic androgen exposure. The Natesto prescribing information notes minimal DHT elevation at recommended doses, making it a rational option for patients whose acne is driven by DHT excess rather than testosterone itself.

If the patient refuses any route change and acne continues to meet Grade 3-4 criteria with QoL impairment after 16 weeks of active dermatologic treatment, discontinuation of AndroGel becomes the appropriate clinical endpoint.

Scarring as an Absolute Clinical Signal

Active scarring, defined as ice-pick, rolling, or boxcar scars forming on the face, chest, or back during ongoing AndroGel therapy, removes most of the ambiguity from the decision tree. Scar formation is irreversible with current therapies. The AAD position on isotretinoin initiation includes active scarring as a qualifying criterion for isotretinoin regardless of total lesion count. When a patient on AndroGel is scarring, the drug is causing permanent physical harm. At that point, continuing AndroGel while pursuing isotretinoin (itself requiring careful monitoring given that both agents stress the liver and lipid panel) is a high-complexity scenario that most prescribers should not attempt without specialist input. Route change or discontinuation plus dermatology co-management is the cleaner clinical path.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. FDA. AndroGel (testosterone gel) 1% and 1.62% Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021015s040lbl.pdf
  2. Bhasin S, et al. Testosterone dose-response relationships in healthy young men. American Journal of Physiology. 2001. https://pubmed.ncbi.nlm.nih.gov/11078502/
  3. Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM. 2018. https://academic.oup.com/jcem/article/103/5/1715/4939016
  4. Rosen T, et al. The Testosterone Trials (TTrials). NEJM. 2016. https://pubmed.ncbi.nlm.nih.gov/26886521/
  5. Zaenglein AL, et al. Guidelines of care for the management of acne vulgaris. JAAD. 2016. https://www.jaad.org/article/S0190-9622(15)02614-6/fulltext
  6. Thiboutot D, et al. Antibiotic use in acne: AAD position statement. JAAD. 2017. https://www.jaad.org/article/S0190-9622(16)30191-7/fulltext
  7. FDA. Isotretinoin (Accutane) Prescribing Information. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018662s059lbl.pdf
  8. FDA. Natesto (testosterone nasal gel) Prescribing Information. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205488lbl.pdf
  9. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clinical and Experimental Dermatology. 1994. https://pubmed.ncbi.nlm.nih.gov/7927017/
  10. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clinical and Experimental Dermatology. 1992. https://pubmed.ncbi.nlm.nih.gov/9620476/
  11. Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. International Journal of Dermatology. 1997. https://pubmed.ncbi.nlm.nih.gov/9692305/
  12. FDA. Guidance for Industry: Acne Vulgaris: Developing Drugs for Treatment (IGA scale). https://www.fda.gov/media/71277/download